Immunotherapy cocktail aims to boost immune attack on prostate tumors before surgery

NCT ID NCT03821246

Recruiting now Disease control Sponsor: David Oh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radical prostatectomy. The goal is to see if these combinations increase tumor-fighting T cells, potentially improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq), tocilizumab (Actemra), etrumadenant (AB928)
What this could lead to: If successful, this could point toward a new way to shrink prostate tumors before surgery, potentially reducing recurrence risk.
What could go wrong: This is an early phase 2 trial with only 68 participants, so results may not apply broadly. The primary endpoint is a biomarker (immune cell increase), not a direct cure or survival benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALIZED PROSTATE CANCER PROSTATE ADENOCARCINOMA PROSTATE CANCER

Contacts and locations

Locations

Alvin J. Siteman Cancer Center at Washington University
RECRUITING

St Louis, Missouri, 63110, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.